164 related articles for article (PubMed ID: 38550295)
1. Prolonged Cancer Control With Adagrasib in Patients With Metastatic,
Stratton N; Thompson J
JTO Clin Res Rep; 2024 Apr; 5(4):100661. PubMed ID: 38550295
[TBL] [Abstract][Full Text] [Related]
2. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
Mausey N; Halford Z
Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
[TBL] [Abstract][Full Text] [Related]
4. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
5. Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.
Yang J; Huang J; Yuan G; Lin XC; Chen HJ; Yang JJ
Clin Case Rep; 2024 Jun; 12(6):e8866. PubMed ID: 38799516
[TBL] [Abstract][Full Text] [Related]
6. CodeBreak 200: Sotorasib Has Not Broken the KRAS
Zhang SS; Lee A; Nagasaka M
Lung Cancer (Auckl); 2023; 14():27-30. PubMed ID: 37101895
[TBL] [Abstract][Full Text] [Related]
7. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
[TBL] [Abstract][Full Text] [Related]
8. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
Iska S; Alley EW
Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS
Chour A; Denis J; Mascaux C; Zysman M; Bigay-Game L; Swalduz A; Gounant V; Cortot A; Darrason M; Fallet V; Auclin E; Basse C; Tissot C; Decroisette C; Bombaron P; Giroux-Leprieur E; Odier L; Brosseau S; Creusot Q; Gueçamburu M; Meersseman C; Rochand A; Costantini A; Gaillard CM; Wasielewski E; Girard N; Cadranel J; Lafitte C; Lebossé F; Duruisseaux M
J Thorac Oncol; 2023 Oct; 18(10):1408-1415. PubMed ID: 37217096
[TBL] [Abstract][Full Text] [Related]
10. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
Desai A; Rakshit S; Bansal R; Ashara Y; Potter A; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Schwecke A; Moffett N; Hocum C; Leventakos K; Adjei A; Marks R; Molina J; Mansfield AS; Chen ZM; Dimou A
Cancer Treat Res Commun; 2023; 36():100743. PubMed ID: 37531736
[TBL] [Abstract][Full Text] [Related]
11. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
[TBL] [Abstract][Full Text] [Related]
12. Adagrasib: a novel inhibitor for
Guo MZ; Marrone KA; Spira A; Rosner S
Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
[TBL] [Abstract][Full Text] [Related]
13. CodeBreaK 200: Sotorasib (AMG510) Has Broken the
Brazel D; Kim J; Ou SI
Lung Cancer (Auckl); 2023; 14():31-39. PubMed ID: 37101896
[TBL] [Abstract][Full Text] [Related]
14. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
[No Abstract] [Full Text] [Related]
15. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R
Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930
[TBL] [Abstract][Full Text] [Related]
16. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
17. First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a
De SK
Curr Med Chem; 2024; 31(3):266-272. PubMed ID: 37005530
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
JCO Precis Oncol; 2024 May; 8():e2400255. PubMed ID: 38748988
[No Abstract] [Full Text] [Related]
19. Severe Immune Checkpoint Inhibitor Hepatitis in
Begum P; Goldin RD; Possamai LA; Popat S
JTO Clin Res Rep; 2021 Sep; 2(9):100213. PubMed ID: 34590053
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers.
O'Leary C; Murphy G; Yeung Y; Tang M; Jain V; O'Leary CG
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]